Analystreport

Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.

Aeglea BioTherapeutics, Inc.  (AGLE) 
Last aeglea biotherapeutics, inc. earnings: 8/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aegleabio.com/investor-overview